Role of the NMDA-receptor in Prepulse Inhibition in the Rat

Overview

Journal Int J Tryptophan Res

Publisher Sage Publications

Specialty Biochemistry

Date 2011 Nov 16

PMID 22084584

Citations 5

Authors

Klas Linderholm

Susan Powell

Elin Olsson

Maria Holtze

Ralph Snodgrass

Sophie Erhardt

Affiliations

Soon will be listed here.

Abstract

Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan. Studies have revealed increased brain KYNA levels in patients with schizophrenia. Prepulse inhibition (PPI) is a behavioral model for sensorimotor gating and found to be reduced in schizophrenia. Previous studies have shown that pharmacologically elevated brain KYNA levels disrupt PPI in the rat. The aim of the present study was to investigate the receptor(s) involved in this effect. Rats were treated with different drugs selectively blocking each of the sites that KYNA antagonizes, namely the glutamate recognition site of the N-methyl-D-aspartate receptor (NMDAR), the α7* nicotinic acetylcholine receptor (α7nAChR) and the glycine site of the NMDAR. Kynurenine (200 mg/kg) was given to replicate the effects of increased levels of KYNA on PPI. In order to block the glutamate recognition site of the NMDAR, CGS 19755 (10 mg/kg) or SDZ 220-581 (2.5 mg/kg) were administered and to antagonize the α7nAChR methyllycaconitine (MLA; 6 mg/kg) was given. L-701,324 (1 and 4 mg/kg) or 4-Chloro-kynurenine (4-Cl-KYN; 25, 50 and 100 mg/kg), a drug in situ converted to 7-Chloro-kynurenic acid, were used to block the glycine-site of the NMDAR. Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI. Kynurenine increased brain KYNA levels 5-fold and tended to decrease PPI. The present study suggests that neither antagonism of the glycine-site of the NMDA receptor nor antagonism of the α7nAChR disrupts PPI, rather with regard to the effects of KYNA, blockade of the glutamate recognition-site is necessary to reduce PPI.

Citing Articles

Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pocivavsek A, Schwarcz R, Erhardt S Pharmacol Rev. 2024; 76(6):978-1008.

PMID: 39304346 PMC: 11549936. DOI: 10.1124/pharmrev.124.000239.

GRK3 deficiency elicits brain immune activation and psychosis.

Sellgren C, Imbeault S, Larsson M, Oliveros A, Nilsson I, Codeluppi S Mol Psychiatry. 2021; 26(11):6820-6832.

PMID: 33976392 PMC: 8760053. DOI: 10.1038/s41380-021-01106-0.

Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task.

Phenis D, Vunck S, Valentini V, Arias H, Schwarcz R, Bruno J Psychopharmacology (Berl). 2020; 237(6):1723-1735.

PMID: 32162104 PMC: 7313359. DOI: 10.1007/s00213-020-05495-y.

Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria.

Holmberg D, Franzen-Rohl E, Idro R, Opoka R, Bangirana P, Sellgren C Malar J. 2017; 16(1):303.

PMID: 28754152 PMC: 5534063. DOI: 10.1186/s12936-017-1954-1.

Influence of pharmacological manipulations of NMDA and cholinergic receptors on working versus reference memory in a dual component odor span task.

MacQueen D, Dalrymple S, Drobes D, Diamond D Learn Mem. 2016; 23(6):270-7.

PMID: 27194794 PMC: 4880146. DOI: 10.1101/lm.041251.115.

References

Rassoulpour A, Wu H, Ferre S, Schwarcz R . Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 2005; 93(3):762-5. DOI: 10.1111/j.1471-4159.2005.03134.x. View

ITIL T, Keskiner A, Kiremitci N, Holden J . Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J. 1967; 12(2):209-12. DOI: 10.1177/070674376701200217. View

Parsons C, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C . Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther. 1998; 283(3):1264-75. View

Swerdlow N, Weber M, Qu Y, Light G, Braff D . Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008; 199(3):331-88. PMC: 2771731. DOI: 10.1007/s00213-008-1072-4. View

Erhardt S, Oberg H, Mathe J, Engberg G . Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids. 2001; 20(4):353-62. DOI: 10.1007/s007260170032. View

Bickford P, Freedman R . Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992; 587(1):130-6. DOI: 10.1016/0006-8993(92)91437-j. View

Chess A, Landers A, Bucci D . L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res. 2009; 201(2):325-31. DOI: 10.1016/j.bbr.2009.03.013. View

Braff D, Stone C, CALLAWAY E, Geyer M, Glick I, Bali L . Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 1978; 15(4):339-43. DOI: 10.1111/j.1469-8986.1978.tb01390.x. View

Jentsch J, Roth R . The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999; 20(3):201-25. DOI: 10.1016/S0893-133X(98)00060-8. View

10.

Erhardt S, Schwieler L, Emanuelsson C, Geyer M . Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004; 56(4):255-60. DOI: 10.1016/j.biopsych.2004.06.006. View

11.

Kretschmer B, Koch M . Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology (Berl). 1997; 130(2):131-8. DOI: 10.1007/s002130050220. View

12.

Nilsson L, Linderholm K, Engberg G, Paulson L, Blennow K, Lindstrom L . Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005; 80(2-3):315-22. DOI: 10.1016/j.schres.2005.07.013. View

13.

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

14.

Erhardt S, Olsson S, Engberg G . Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs. 2009; 23(2):91-101. DOI: 10.2165/00023210-200923020-00001. View

15.

Schwieler L, Linderholm K, Nilsson-Todd L, Erhardt S, Engberg G . Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 2008; 83(5-6):170-5. DOI: 10.1016/j.lfs.2008.05.014. View

16.

Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G . Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons--possible involvement of endogenous kynurenic acid. Synapse. 2006; 59(5):290-8. DOI: 10.1002/syn.20241. View

17.

Paylor R, Nguyen M, Crawley J, Patrick J, Beaudet A, Orr-Urtreger A . Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem. 1999; 5(4-5):302-16. PMC: 311270. View

18.

Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom L, Engberg G . Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001; 313(1-2):96-8. DOI: 10.1016/s0304-3940(01)02242-x. View

19.

Bakshi V, Tricklebank M, Neijt H, Geyer M . Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. J Pharmacol Exp Ther. 1999; 288(2):643-52. View

20.

Guillemin G, Kerr S, Smythe G, Smith D, Kapoor V, Armati P . Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001; 78(4):842-53. DOI: 10.1046/j.1471-4159.2001.00498.x. View